42817-60-7

Usage

Uses

Used in Organic Synthesis:
N-[3-(4-aminophenyl)propyl]-N,N-dimethylamine (min. 90% purity) is used as a building block in organic synthesis for the creation of various chemical compounds.
Used in Pharmaceutical Manufacturing:
N-[3-(4-AMINOPHENYL)PROPYL]-N,N-DIMETHYLAMINE(MIN.90%PURITY) is utilized as an intermediate in the production of drugs, playing a crucial role in the development of pharmaceuticals.
Used in Polymer Production:
N-[3-(4-aminophenyl)propyl]-N,N-dimethylamine (min. 90% purity) is also employed as an intermediate in the synthesis of polymers, contributing to the manufacturing of various polymeric materials.
It is important to handle this chemical with proper care and follow safety protocols, as it can be hazardous if not handled properly.

Upstream product

• 1613708-50-1 3-(4-nitrophenyl)prop-2-yn-1-amine hydrochloride 
• 1350564-22-5 tert-butyl (3-(4-nitrophenyl)prop-2-yn-1-yl)carbamate 
• 7223-38-3 N,N-Dimethylpropargylamin 
• 7647-01-0 hydrogenchloride 
• 65228-49-1 N,N-dimethyl-3-(4-nitrophenyl)propylamine 

Downstream Products

• 872511-39-2 N-[4-(3-dimethylamino-propyl)phenyl]-N'-methylpyrimidine-4,6-diamine 
• 1613708-27-2 C₄₁H₅₂N₄O₅ 
• 1613708-07-8 C₄₁H₄₈N₄O₅ 
• 1613708-30-7 C₃₉H₅₅ClN₁₀O₄ 
• 1613708-29-4 C₃₃H₅₀N₄O₃*C₂H₄O₂ 
• 1613708-09-0 C₃₉H₅₁ClN₁₀O₄ 
• 1613708-08-9 C₃₃H₄₆N₄O₃ 
• 1613707-31-5 C₃₉H₅₁ClN₁₀O₄ 
• 1613707-30-4 C₃₃H₄₆N₄O₃ 
• 1613707-29-1 C₄₁H₄₈N₄O₅ 
• 1125393-76-1 C₃₅H₃₁F₂N₇O 
• 73278-94-1 N,N-dimethyl-3-(4-hydroxyphenyl)propylamine 

Relevant academic research and scientific papers

CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY

This invention provides compounds of the formula I: and their pharmaceutically acceptable salts, useful as sodium channel blockers, compositions containing the same, therapeutic methods and uses for the same and processes for preparing the same.

Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl- piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase

A novel series of N-aryl-N′-pyrimidin-4-yl ureas has been optimized to afford potent and selective inhibitors of the fibroblast growth factor receptor tyrosine kinases 1, 2, and 3 by rationally designing the substitution pattern of the aryl ring. On the b

PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS

The invention relates to compounds of formula (I) wherein the substituents X1, R1, R2, R3 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.

Synthesis, pharmacological and biophysical characterization, and membrane-interaction QSAR analysis of cationic amphiphilic model compounds

Cationic amphiphilic drugs have a propensity to interact with biological interphases. This study was designed to gain more insight into the molecular properties of catamphiphilic drugs which govern this type of interaction. A series of phenylpropylamine model compounds were synthesized in which modifications were incorporated at the aromatic part of the molecule. The replacement of 45Ca2+ from phosphatidylserine monolayers served to monitor drug binding to the phospholipid. The influence on the phase- transition temperature of liposomes of dipalmitoylphosphatidic acid was measured to assess the perturbing action of the drugs on the structural organization of phospholipid assemblies. The antiarrhythmic activity of the compounds was determined in Langendorff preparations of guinea pig hearts to assess the membrane-stabilizing action. Quantitative structure-activity relationship (QSAR) models for these endpoints were developed using both intra- and intermolecular QSAR descriptors. Intermolecular membrane- interaction descriptors were derived from molecular dynamics simulations of the compounds in a model phospholipid monolayer. QSAR models were derived for all endpoints using partial least-squares regression (PLS) and a genetic algorithm tool, the genetic function approximation (GFA). Membrane- interaction descriptors appear to be of a particular importance in explaining the influence of the compounds on the phase-transition temperature of DPPA liposomes, while the other endpoints can be adequately modeled by intramolecular descriptors. The calcium-displacing activity at phosphatidylserine monolayers is governed by the electrostatic properties of the compounds. Measures of lipophilicity and molecular size are of particular importance for antiarrhythmic activity. Possible improvements to both the molecular modeling and the applied computational protocol of membrane-solute systems are identified and discussed.